quoting delegate and company name - Sachs Associates

With Speaker Participation From:
Advanced Technology Ventures
Advent International Corporation
Ascension Health Ventures
AstraZeneca Pharmaceuticals
Atlas Venture
Bank of America
Beyond Genomics
BioEnterprise Asia
BioExec Ventures, LLC
Biotech Consortium India Limited
Boston Millennia Partners
CDP Capital – Technology Ventures
Fish & Richardson P.C.
Flagship Ventures
Friedman Billings Ramsey
Genzyme Corporation
Global Markets Capital Corporation
HarbourVest Partners LLC
Harvard Clinical Research Institute
Harvard Medical School
Idenix Pharmaceuticals, Inc.
Imperial College Innovations Ltd
Infinity Pharmaceuticals
INSTITUT PASTEUR
International Finance Corporation
Invest Australia
Katan Associates
Kirkpatrick & Lockhart LLP
Massachusetts Institute of Technology
Merck Research Laboratories
Merrimack Pharmaceuticals
Monument Group
MPM Capital
National Institutes of Health
Nomura
Novartis Institutes for Biomedical
Research
Oxford Bioscience Partners
Pfizer Global R&D
Polaris Venture Partners
Schroder Ventures Life Sciences
SG Cowen Securities Corporation
Shenzhen ChipScreen
Biosciences Ltd
Sofinnova Partners
Warburg Pincus LLC
Womble Carlyle Sandridge
& Rice PLLC
Zero Stage Capital
Presenting Companies Include:
AnorMED, Inc.
atugen AG
Aureon Biosciences Corporation
BIOCORTECH
Biota Holdings, Ltd.
BioVex Limited
Cellectis SA
Concurrent Pharmaceuticals
Curis, Inc.
Cyclacel Ltd
Dermatrends, Inc.
DeveloGen AG
Ecopia BioSciences, Inc.
GenOdyssee
Generex Biotechnology Corporation
Genstruct, Inc.
Global Genomics AB
Hybrigenics
Immunitor USA Inc.
IsoTis
LifePoint, Inc.
MacroChem Corporation
MethylGene, Inc.
Munich Biotech AG
Newron Pharmaceuticals SpA
Nuevolution A/S
Opexa Pharmaceuticals, Inc.
Oxxon Pharmaccines
Predix Pharmaceuticals Holdings, Inc.
Serenex, Inc.
Viral Therapeutics, Inc.
3rd Annual
GLOBAL BIOTECH FORUM for
INVESTING & PARTNERING
For Venture Capitalists, Fund Managers & Institutional Investors
1 st -2 nd April 2004 • The Fairmont Copley Plaza, Boston
Event Sponsors:
AstraZeneca Pharmaceuticals www.astrazeneca.com
BioExec Ventures, LLC www.bioexec.com
Fish & Richardson P.C. www.fr.com
Invest Australia www.investaustralia.gov.au
Katan Associates www.katanassociates.com
Kirkpatrick & Lockhart LLP www.kl.com
Corporate Sponsors:
AnorMED Inc. www.anormed.com IsoTis www.isotis.com
Curis, Inc. www.curis.com LifePoint, Inc. www.lifepointinc.com
Ecopia BioSciences, Inc. www.ecopiabio.com MacroChem Corporation www.macrochem.com
Generex Biotechnology Corporation www.generex.com
Main Media Partners:
Media & IR Partners:
www.biocommerce.com
www.nature.com/naturebiotechnology
www.investinbiotech.com
www.bioventureview.com
www.biowire2K.com
Conference Partners:
www.biolawbusiness.com
www.bioworld.com
www.thebiotechclub.org
www.nature.com/reviews/drugdisc
www.lavoiegroup.com
www.massbio.org
www.ronaldtrahan.com
www.troutgroup.com
For latest update information visit: www.sachsforum.com

EVENT SPONSORS
www.investaustralia.gov.au
www.katanassociates.com
AnorMED
www.anormed.com
www.curis.com
www.ecopiabio.com
www.generex.com
www.astrazeneca.com
www.bioexec.com
www.fr.com
www.kl.com
CORPORATE SPONSORS
GLOBAL BIOTECH FORUM FOR
www.isotis.com
www.lifepointinc.com
www.macrochem.com
For Venture Capitalists, Fund Ma
1 st -2 nd April 2004 • The Fair
Biotechnology: From the Benchtop to the Boardroom
The Key Steps for Early Stage Commercialization for Pre-Phase II Opportunities
Pre-Conference Workshop: Wednesday 31st March 2004 14.30 – 18.30
Led by: Stan Yakatan, Chairman & Seth Yakatan, Partner, Katan Associates
• John N. Vournakis, Ph.D., Vice President for Research and Development, Marine Polymer
Technologies, Inc. and Professor of Graduate Studies at the Medical University of South Carolina
This workshop provides a comprehensive framework for understanding & putting into practice
the key elements to commercialization.
For full workshop synopsis, please contact Pernilla Hellsten on +44 207 405 5544 or Pernilla@sachsforum.com
Please see overleaf for registration details.
T HURSDAY 1 ST A PRIL 2004
7.45 Registration
8.25 Chairman’s Welcome: P. Louis Myers, Ph.D., Principal, Fish & Richardson P.C.
8.30 – Opening Panel: Venturing Financing Outlook for Biotech in 2004
9.20 Chair: Michael Lytton, General Partner, Oxford Bioscience Partners
• Jean M. George, Partner, Advanced Technology Ventures
• Dr. Christoph H. Westphal, General Partner, Polaris Venture Partners
• James M. Garvey, CEO & Managing Partner, Schroder Ventures Life Sciences
• Ben Bronstein, Managing Director, Zero Stage Capital
PRIVATE EQUITY AND THE LISTED MARKETS
9.20 Stelios Papadopoulos, Ph.D., Vice Chairman, SG Cowen Securities Corporation
9.40 – Panel: Capital Markets
10.25 • Michael King, Managing Director, Healthcare Group, Bank of America
• R. Nelson Campbell, Senior Vice President, Life Sciences Investment Banking,
Friedman, Billings, Ramsey
• Dr. Sam Fazeli, Senior Biotechnology Analyst, Nomura
10.25 Break
10.45 – Small-Cap/Listed Company Presentations
12.45
Chair: P. Louis Myers, Ph.D., Principal, Chair: Roger Feldman
Fish & Richardson P.C. Fish & Richardson P.C
AnorMed, Inc. IsoTis
Curis, Inc. LifePoint, Inc.
Ecopia BioSciences, Inc. MacroChem Corporation
OPTIONAL
WORKSHOP
12.45
Generex Biotechnology Corporation
Lunch
BIOPARTNERING & COLLABORATION
14.00 – Panel: Evolving Pharma / Biotech Relationships
14.50 Chair: Eileen Smith Ewing, Esq, Partner & Chair, Life Sciences Group,
Kirkpatrick & Lockhart LLP
• Dr. Maggie Flanagan, Global Alliance Director, Enabling Science, Technology and
Information, AstraZeneca Pharmaceuticals
• Jan van Heek, Executive Vice President, Therapeutics & Genetics, Genzyme Corporation
• Jeremy Levin, Global Head of Strategic Alliances,
Novartis Institutes for Biomedical Research
• Dr. Ravi Kiron, Global Head, Strategic Analysis & Knowledge Management Strategic
Alliances, Pfizer Global R&D
SECTOR WORKSHOPS: EARLY-STAGE COMPANY PRESENTATIONS
15.00 – Workshop I: Workshop II: Workshop III:
16.35 Immunology / Oncology
Chair: Donna L. LaVoie,
President & CEO,
LaVoie Strategic
Communications Group, Inc.
Therapeutics Post-Genomics
FUND OF FUNDS
16.45– Panel: Fund of Funds
17.30 Chair: William C. Mills III, Partner, Advent International
• Matthew I. Hermann, Director, Strategic Health Venture Investing,
Ascension Health Ventures
• Gregory V. Stento, Managing Director, HarbourVest Partners LLC
• Robert E. Mast, Managing Director, Monument Group
• Otello Stampacchia Ph.D., Head of Life Sciences Investments, NIB Capital Private Equity

INVESTING & PARTNERING
nagers & Institutional Investors
mont Copley Plaza, Boston
day one continued...
GLOBAL DEVELOPMENT
17.30 – Panel: Global Development
18.30 International Perspectives on Venture Investing and the Development of Regional Life
Science Markets
Chair: N. Peter Kostopulos, Leader BioAlliance Practice & Partner Life Sciences,
Womble Carlyle
• Pierre Cantin, Partner, Biotechnology & Life Sciences, CDP Capital – Technology Ventures
• Mark R. Saunders, President, Global Markets Capital Corporation
• Antoine Papiernik, General Partner, Sofinnova Partners
• Stewart Hen, Managing Director, Warburg Pincus LLC
18.30 Cocktail Party
F RIDAY 2 ND A PRIL 2004
7.45 Registration
8.25 Chairman’s Welcome
TECHNOLOGY TRANSFER
8.30 Theodore J. Roumel, Office of Technology Transfer, National Institutes of Health
8.45 – Panel: Technology Transfer
9.30 Successfully Transferring Technology into the Marketplace
Chair: Lita Nelsen, Director, Technology Licensing Office,
Massachusetts Institute of Technology
• O.Prem Das, Ph.D., Director, Office of Technology Licensing & Industry Sponsored Research,
Harvard Medical School
• Dr. John Burt, Head Medical Sciences Team, Imperial College Innovations
• Jean Pierre Saintouil, Director, Office of Technology Transfer,
INSTITUT PASTEUR – Paris, France
9.30 – KEYNOTE PANEL:
10.30 Value Creation in Biotechnology
Introduced by: Hoda Abou-Jamra, Founder & CEO, BioExec Ventures, LLC
Chair: Jean-François Formela, Senior Partner, Atlas Venture
Chair: Ansbert Gadicke, MD, Founding General Partner & Chairman, MPM Capital
• Noubar B. Afeyan, Ph.D., Senior Managing Director & CEO, Flagship Ventures
• Jean-Pierre Sommadossi, Ph.D., Founder, CEO & Chairman, Idenix Pharmaceuticals
• Steven Holtzman, CEO, Infinity Pharmaceuticals
• Dr. Edward M. Scolnick, President Emeritus, Merck Research Laboratories
10.30 Break
SECTOR WORKSHOPS: COMPANY PRESENTATIONS
10.45 Workshop IV: Immunology/Oncology Workshop V: Therapeutics
Private Company Presentations Private Company Presentations
12.30 Lunch
DRUG DISCOVERY & DEVELOPMENT
14.00 Panel: Clinical Trials & Drug Development
Assessing the Cost of Clinical Trials & Identifying The Key Issues in Drug Development
Richard E. Kuntz, MD, M, Chief Scientific Officer, Harvard Clinical Research Institute, Chief,
Division of Clinical Biometrics, Brigham & Women’s Hospital, Associate Professor Medicine,
Harvard Medical School
14.15 – Panel: Systems Biology
15.15 Is This The Right Time To Invest?
Chair: Dr. James Fickett, Director, Strategic Capabilities, Discovery IS and Informatics,
AstraZeneca Pharmaceuticals
• Stephen Ober, President, Beyond Genomics, Inc.
• Dr. Robert Mashal, Partner, Boston Millennia Partners
• Robert Mulroy, President & CEO, Merrimack Pharmaceuticals
EMERGING MARKETS
15.15 – Panel: Emerging Markets
16.15 Examining The Growth of Biotech Industries in Asia-Pacific, Australia, China, India
Chair: Stan Yakatan, Chairman, Katan Associates
• Dr. Vibha Ahuja, Deputy General Manager, Biotech Consortium India Limited
• Dr. Gurinder S. Shahi, MBBS, Ph.D., MPH, CEO & Principal Consultant, BioEnterprise Asia
• Mario Gobbo, Head of Life Sciences, International Finance Corporation
• Dr. Nathan Xin Zhang, President, Shenzhen ChipScreen Biosciences Ltd
16.15 Close of Conference
PRESENTING COMPANIES
www.atugen.com
www.aureon.com
www.biocortech.com
www.biota-inc.com
www.biovex.com
www.cellectis.com
www.concurrentpharma.com
www.cyclacel.com
www.develogen.com
www.dermatrends.com
www.genodyssee.com
www.genstruct.com
www.globalgenomics.com
www.hybrigenics.com
www.immunitor.com
www.methylgene.com
www.munichbiotech.com
www.newron.com
www.nuevolution.com
www.opexapharma.com
www.oxxonpharmaccines.com
www.predixpharm.com
www.serenex.com
www.viral-therapeutics.com
For an update on the companies presenting,
panel timings and the latest agenda,
please visit our website www.sachsforum.com
PRESENTATION OPPORTUNITIES
Each workshop is sector/industry based and will
feature Start-up to Pre-IPO company presentations.
Should you wish to PRESENT your company
in a sector workshop please contact
Bernd Strenitz at Bernd@sachsforum.com
EXHIBITION OPPORTUNITIES
Should you wish to exhibit at this Forum
please contact info@sachsforum.com

REGISTRATION FORM
COMPLETE AND RETURN BY 25 MARCH 2004:
By post: Pernilla Hellsten
Sachs Associates
Oldebourne House
46-47 Chancery Lane
London WC2A 1JB
By fax: +44 (0)20 7405 4411
DELEGATE DETAILS
One form per person (photocopy as necessary). BLOCK CAPITALS.
Surname ___________________________________________ Dr/Mr/Ms___________________________________
First Name ___________________________________________________________________________________________
Job Title ______________________________________________________________________________________________
Organisation _________________________________________________________________________________________
Address ______________________________________________________________________________________________
_________________________________________________________________________________________________________
Postcode _______________________________ Country _____________________________________________
Tel _______________________________________ Fax ___________________________________________________
Email __________________________________________________________________________________________________
Signature __________________________________________________________________________________________________________________________
COST
Cost per delegate is: ■ Conference ONLY – $1,195.
■ Conference and Workshop – $1,495.
■ Workshop ONLY – $ 395.00.
Discounts available for groups of 3 or more.
METHODS OF PAYMENT
Payment must be received with booking to guarantee your place.
Please tick one payment option:
(After 19th March 2004 ONLY credit card payments will be accepted)
■ BANK TRANSFER (quoting delegate and company name) to credit:
Sachs Associates Ltd, NatWest Bank
Bouverie House Branch, 156 Fleet Street, London EC4A 2LL, UK
Sort Code 50-21-16
Dollar Account No: 140-01-40053768 Swift Code: NWBKGB2LXXX
Correspondent Bank USA: JP Morgan Chase
IBAN: GB95 NWBK 6073 0140 0537 68
Please fax confirmation of bank transfer to PERNILLA HELLSTEN on:
+44 (0)20 7405 4411, (quoting delegate name and company name).
■ CREDIT CARD American Express ■ Visa/Mastercard ■
(Please note all payments by Visa/Mastercard will be processed in Sterling at current rate).
Card No. ■■■■■■■■■■■■■■■■
Expiry Date _______________________________________________________________
Name (as it appears on card) ____________________________________________
Card Billing Address ___________________________________________________
____________________________________________________________________
___________________________________ Postcode ______________________
How did you hear about the conference? Please tick appropriate box.
■ Publication (please specify) _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
■ www.sachsforum.com ■ Bloomberg
■ Fax/Email/Mail ■ Other (please specify) _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
SACHS ASSOCIATES – is a London-based company
which organises international investment conferences
in association with Bloomberg LP. Sachs Associates
is dedicated to the highest quality standards in
conferencing and, as a result, produces only a limited
number of high-profile events each year.
Sachs Associates investment conferences focus on Growth Sector companies
(Biotechnology and Technology), Emerging Markets and Venture Markets. These
events are held in major financial centres such as Frankfurt, London, Munich,
New York and Zurich.
Tel: +44 (0)20 7405 5544; www.sachsforum.com
VENUE
The conference will take place in The Fairmont Copley Plaza,
138 St. James Avenue, Boston, MA 02116, USA.
Tel: +1 617 267 5300 Fax: +1 617 247 6681
REGISTRATION
Delegates may register from 07.45am on Thursday 1st and Friday 2nd April
2004 at the registration desk in the corridor outside the Grand Ballroom.
The Grand Ballroom is situated on the lobby level of the hotel. Upon arrival at
the venue please go immediately to the Sachs Associates Registration Desk.
Please bring a copy of your confirmation letter.
ACCOMMODATION
Special rates have been negotiated at The Fairmont Copley Plaza for
delegates requiring overnight accommodation. This is a limited allocation
and is subject to availability. To obtain special rates, please call the
reservations department on +1 617 267 5300, quoting GRSAC1.
You can also book online, quoting the same code in the box ‘Promotional
Code’ on the reservations page at www.fairmont.com.
COCKTAIL RECEPTION
There will be a cocktail party on Thursday 1st April at the close of the
conference on Day One in the Oval Room. All delegates are welcome.
EXHIBITION SPACE
Exhibition space is available at the conference. For further details call
Pernilla Hellsten on +44 (0)20 7405 5544.
DUPLICATE MAILINGS
Every effort has been made to ensure that you do not receive duplicate
mailings. However certain databases cannot be cross-referenced. If you
have received more than one copy, please accept our apologies and pass it
on to your colleagues for their information.
HOW TO REGISTER
Please complete the attached registration form and return with payment either:
By post to: Or by fax: +44 (0) 20 7405 4411
Pernilla Hellsten
Sachs Associates
Oldebourne House
46-47 Chancery Lane
London WC2A 1JB
HOW TO PAY
Delegate Fee
The cost per delegate is $1195. Discounts available for groups of 3 or more.
After 19th March 2004 ONLY credit card payments will be accepted.
(Please note that all payments by VISA/Mastercard will be processed
in Sterling at the current rate.)
There will be no admittance to the conference without prior payment.
SUBSTITUTIONS AND CANCELLATIONS
Substitutions may be made at any time with written notification. You may
cancel your registration with a full refund less a $100 service charge,
provided we have received WRITTEN NOTIFICATION no later than Friday
19th March 2004. Thereafter cancellations will be charged to the full
registration fee.
ENQUIRIES
If you have any queries concerning the conference please call
Pernilla Hellsten on +44 (0)20 7405 5544.
Please note that the programme is provisional and subject to
amendments.
BLOOMBERG LP – is a unique global, multimediabased
distributor of information services,
combining news, data and analysis for global
financial markets and businesses. Bloomberg provide real-time pricing, data,
history, analytics and electronic communications 24 hours a day, 365 days a year
and is used by over 200,000 financial professionals in 90 countries worldwide.
Bloomberg, the world’s fastest growing real-time information provider, delivers a
unique service to the financial markets of the world. The Bloomberg terminal is
an essential tool for investors and other professionals planning to take
advantage of the opportunities in Emerging Markets.
Tel: +44 (0)20 7330 7500; www.bloomberg.com